BRAIN and NERVE－神経研究の進歩71巻6号

2019年06月発行

特集 補体標的治療の現状と展望

補体とアルツハイマー病

著者： 冨本秀和¹ 秋山治彦²

所属機関： ¹三重大学大学院医学系研究科神経病態内科学 ²横浜市立脳卒中・神経脊椎センター臨床研究部

ページ範囲：P.589 - P.596

文献概要

補体はアルツハイマー病の老人斑，神経原線維変化，血管に沈着する。これらの構造とその周囲では活性化ミクログリアがアストログリアとクロストークして慢性炎症を惹起する。アミロイドβ（Aβ）によって活性化した補体はミクログリアの補体受容体（CR3）と反応し，凝集Aβをオプソニン化してミクログリアの貪食機能を助けている。毛細血管型アミロイド血管症（CAA）の炎症はアミロイドクリアランス機能を抑制し，CAAをより増悪する悪循環となる。

参考文献

1)Veerhuis R, Nielsen HM, Tenner AJ: Complement in the brain. Mol Immunol 48: 1592-1603, 2011

2)McGeer PL, Rogers J, McGeer EG: Inflammation, antiinflammatory agents, and Alzheimer's disease: the last 22 years. J Alzheimers Dis 54: 853-857, 2016

3)McGeer PL, Lee M, McGeer EG: A review of human diseases caused or exacerbated by aberrant complement activation. Neurobiol Aging 52: 12-22, 2017

4)Morgan BP: Complement in the pathogenesis of Alzheimer's disease. Semin Immunopathol 40: 113-124, 2018

5)Eikelenboom P, Stam FC: Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol 57: 239-242, 1982

6)Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, et al: Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421, 2000

7)Liu S, Suzuki H, Ito H, Korenaga T, Akatsu H, et al: Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment. Alzheimers Dement (Amst) 11: 85-97, 2019

8)Akiyama H, Mori M, Saido T, Kondo H, Ikeda K, et al: Occurrence of the diffuse amyloid β protein (Aβ) deposits with numerous Aβ-containing glial cells in the cerebral cortex of patients with Alzheimer's disease. Glia 25: 324-331, 1999

9)Tacnet-Delorme P, Chevallier S, Arlaud GJ: Beta-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A beta on the C1q globular regions. J Immunol 167: 6374-6381, 2001

10)Lian H, Litvinchuk A, Chiang AC, Aithmitti N, Jankowsky JL, et al: Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in mouse models of Alzheimer's disease. J Neurosci 36: 577-589, 2016

11)Lian H, Yang L, Cole A, Sun L, Chiang AC, et al: NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease. Neuron 85: 101-115, 2015

12)Veerhuis R, Janssen I, Hack CE, Eikelenboom P: Early complement components in Alzheimer's disease brains. Acta Neuropathol 91: 53-60, 1996

13)Fonseca MI, Kawas CH, Troncoso JC, Tenner AJ: Neuronal localization of C1q in preclinical Alzheimer's disease. Neurobiol Dis 15: 40-46, 2004

14)Reichwald J, Danner S, Wiederhold KH, Staufenbiel M: Expression of complement system components during aging and amyloid deposition in APP transgenic mice. J Neuroinflammation 6: 35, 2009［doi: 10.1186/1742-2094-6-35］

15)Itagaki S, Akiyama H, Saito H, McGeer PL: Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res 645: 78-84, 1994

16)Eikelenboom P, Zhan SS, Kamphorst W, van der Valk P, Rozemuller JM: Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid plaques in Alzheimer's disease. Virchows Arch 424: 421-427, 1994

17)Sjöberg AP, Trouw LA, Blom AM: Complement activation and inhibition: a delicate balance. Trends Immunol 30: 83-90, 2009

18)Xiong F, Ge W, Ma C: Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer's disease. Alzheimers Dement 15: 429-440, 2019

19)Banz Y, Rieben R: Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann Med 44: 205-217, 2012

20)Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, et al: The classical complement cascade mediates CNS synapse elimination. Cell 131: 1164-1178, 2007

21)Shinjyo N, Ståhlberg A, Dragunow M, Pekny M, Pekna M: Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. Stem Cells 27: 2824-2832, 2009

22)Benoit ME, Tenner AJ: Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J Neurosci 31: 3459-3469, 2011

23)Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, et al: Complement C3-deficient mice fail to display age-related hippocampal decline. J Neurosci 35: 13029-13042, 2015

24)Chu Y, Jin X, Parada I, Pesic A, Stevens B, et al: Enhanced synaptic connectivity and epilepsy in C1q knockout mice. Proc Natl Acad Sci U S A 107: 7975-7980, 2010

25)Fonseca MI, Zhou J, Botto M, Tenner AJ: Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci 24: 6457-6465, 2004

26)Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, et al: Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352: 712-716, 2016

27)Verbeek MM, Otte-Höller I, Veerhuis R, Ruiter DJ, De Waal RM: Distribution of A beta-associated proteins in cerebrovascular amyloid of Alzheimer's disease. Acta Neuropathol 96: 628-636, 1998

28)Matsuo K, Shindo A, Niwa A, Tabei KI, Akatsu H, et al: Complement activation in capillary cerebral amyloid angiopathy. Dement Geriatr Cogn Disord 44: 343-353, 2017

29)Endo Y, Hasegawa K, Nomura R, Arishima H, Kikuta KI, et al: Apolipoprotein E and clusterin inhibit the early phase of amyloid-β aggregation in an in vitro model of cerebral amyloid angiopathy. Acta Neuropathol Commun 7: 12, 2019［doi: 10.1186/s40478-019-0662-1］

30)Uchida K, Shan L, Suzuki H, Tabuse Y, Nishimura Y, et al: Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline. Alzheimers Dement (Amst) 1: 270-280, 2015

31)Hakobyan S, Harding K, Aiyaz M, Hye A, Dobson R, et al: Complement biomarkers as predictors of disease progression in Alzheimer's Disease. J Alzheimers Dis 54: 707-716, 2016

32)Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, et al: Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12: 554-562, 2013